C-Reactive Protein Levels Decrease Rapidly in Patients With Crohn's Disease Treated With Adalimumab: Presented at ACG
By Ed Susman
WASHINGTON, DC -- November 3, 2011 -- When patients with active Crohn’s disease are treated with the biologic agent adalimumab, the levels of C-reactive protein drops dramatically, researchers said here October 30 at the 2011 Annual Scientific Meeting of the American College of Gastroenterology (ACG).
“Adalimumab induction therapy was associated with rapid and significant reductions -- within 4 weeks -- in C-reactive protein levels among patients with moderate to severe Crohn’s disease,” noted Subrata Ghosh, MD, University of Calgary, Calgary, Alberta.
In the 767 patients with moderate to severe Crohn’s disease, baseline C-reactive protein levels were measured at a mean of 2.15 mg/dL among, which then fell to 1.17 mg/dL at the end of 4 weeks (P <.001).
Among the 367 patients diagnosed with moderate Crohn’s disease, the baseline C-reactive protein levels was 1.63 mg/dL, and that was reduced to 1.04 mg/dL after 4 weeks of treatment with adalimumab (P <.001).
For the study, researchers defined moderate to severe Crohn’s disease as those patients who had Crohn’s Disease Activity Index (CDAI) scores between 220 and 450; the moderate Crohn’s disease population was defined at those patients with scores <300 on the CDAI.
“For patients with early C-reactive protein improvement at week 4, adalimumab therapy was associated with significantly greater long-term clinical benefit at week 56 versus placebo,” the researchers reported.
Dr. Ghosh reviewed data from the Crohn’s Trial of the Fully Human Antibody Adalimumab for Remission Maintenance (CHARM). “A significant association between C-reactive protein concentrations at diagnosis and risk of surgery has been reported for patients with Crohn’s disease,” he noted. “Changes in C-reactive protein concentration have been used to monitor treatment efficacy in patients with Crohn’s disease.”
Among patients with C-reactive protein improvement -- defined as a reduced of more than 1 mg/dL from baseline to week 4 -- the remission rate at week 56 was 35.8% for patients receiving adalimumab and 9.1% for patients receiving placebo (P <.001).
Funding for the study was provided by Abbott Laboratories.
[Presentation title: C-Reactive Protein Levels in Moderate to Severe Crohn’s Disease Patients Decreased Rapidly and Significantly During Adalimumab Therapy. Abstract P301]